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Introduction
Patients with Guillain-Barré syndrome (GBS), chronic
relapsing polyneuropathies (CRP) and hereditary
neuropathy with liability to pressure palsy (HNPP)
may experience recurrent episodes.1–3 However,
recurrence is uncommon in other types of poly-
neuropathies. The etiologies of CRP and GBS have
been considered to involve immunologic reactions
revealed by pathologic findings, although the true
pathogeneses are unknown.3–5 In contrast, HNPP is a
genetic disorder for which inflammatory reactions are
not evident in pathology.6,7 Nevertheless, it has been
reported that HNPP can manifest as recurrent
polyradiculoneuropathy.8 It has been suggested that a
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peripheral myelin protein 22 (PMP22) gene deletion
might play a role in the pathogenesis of some chronic
or recurrent polyradiculoneuropathies. We performed
molecular studies on 4 patients who presented with
recurrent polyradiculoneuropathies to further elucidate
this finding.
Methods
Patients
Between 1993 and 2003, 114 patients were admitted to
our institute with polyradiculoneuropathy or its var-
iants. These included 70 patients with GBS, 13 with
Miller-Fisher syndrome (MFS), and 31 with chronic
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inflammatory demyelinating polyradiculoneuropa-
thies (CIDP). They were diagnosed through clinical
manifestations, electrophysiologic studies and cere-
brospinal fluid examinations with or without nerve
biopsy. Of these 114 patients, 4 had recurrent attacks
(Table 1; Figure 1).
The first, male, patient suffered from 3 similar
attacks with acute distal limb numbness and weakness
for days. These 3 incidents happened when he was in
his fifties, at the age of 64 years, and when he was 75
years old. Complete recovery was noted each time
with or without treatment.
The second, male, patient had 5 attacks with 4
episodes of limb weakness and bilateral hand numbness
lasting for months at the ages of 59, 60 (2 times, 7
months apart), 61 and 68 years. Complete recovery
within several months was achieved each time, but
with different management.
The third, also male, patient was first admitted to
our department in March 1982 due to acute generalized
paralysis and respiratory failure when he was 43 years
old. Similar events occurred in September 1988, March
1992 and February 1996. He resumed his work in the
intervals between events.
Table 1. Clinical manifestations and findings from cerebrospinal fluid (CSF) examination, nerve pathology and
electrophysiologic studies in 4 patients with recurrent polyradiculoneuropathies
Patient Gender
Age (yr)
Clinical manifestations Sural nerve biopsy
CSF protein*
Electrodiagnosis
at occurrence (mg/dL)
1 Male 53, 64 Limb weakness, numbness, areflexia Not done 54 Demyelination
2 Male 51†, 52†, 53, 60 Limb weakness, numbness, areflexia Demyelination 62 Demyelination
3 Male 29, 35, 38, 42 Quadriparalysis, respiratory failure, areflexia Demyelination 34 Demyelination
4 Female 13, 14 Bilateral lower limb weakness, Demyelination, 145 Demyelination
numbness, areflexia onion bulb formation
*Normal range = 15–45 mg/dL, data is from first attack; †2 episodes at the same age.
Figure 1. Pathology of the sural nerve: (A) Patient 2 – demyelination
can be seen in 2 fibers (arrowheads); (B) Patient 3 – fiber
(arrowhead) shows demyelination; (C) Patient 4 – fibers
(arrowheads) show demyelination and remyelination. (Toluidine
blue stain; bar in bottom right-hand corner = 10 μm.)
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The last patient, a 14-year-old girl, was admitted to
our hospital in July1994 due to progressive weakness
of the lower limbs and right hand for more than 2
months. She was readmitted because of progressive
bilateral lower limb weakness and numbness for 3
weeks in July 1995. Her condition improved gradually,
but mild sensory impairment and weakness remained.
Absence of general tendon reflex was noted in all 4
patients during examination. Nerve conduction study
(NCS) showed demyelinating changes with prolonged
distal latencies and F waves, and decreased nerve
conduction velocity (NCV) and relatively spared
amplitudes. All 4 patients received more than 1 NCS
study. Compared with the first NCS evaluation, the
subsequent NCS performed in patient 1 disclosed
shorter distal latencies and F responses, and faster
NCV. The subsequent NCS in patient 2, who had no
clinical recurrent episodes, did not show improvement.
In patient 3, improvement was noted on NCS. In
patient 4, the last NCS did not show any improvement
compared with earlier NCS, although no clinical
episodes of recurrence were reported.
DNA analysis
Genomic DNA was extracted from the peripheral
lymphocytes of all 4 patients using a previously
described procedure,9 and molecular detection of
PMP22 deletion was performed as described by
Haupt et al10 and Latour et al.11 The point mutation
detection of the PMP22 gene coding region was
sc reened  by  in t ron ic  p r imer s  1 - fo rward
CATATCCCAGCATTGGACCAGC, 1-backward
ATAGGCACACATCACCCAGAG, 2-forward
CGTTCGGCCTCACGCCCAGC, 2-backward
G G A A C C C A G A T G G G G A A G ,  3 - f o r w a r d
TTTCCTTCACTCCTCCCTCC, 3-backward
TGAGGACAAGCTCATGGAGC, 4-forward
CCATGGCCAGCTCTCCTAAC, 4-backward
CATTCCGCAGACTTTGATGC, 5-forward
CCAGCAATTGTCAGCATCC; 5-backward
ACGCTCAGAGCCTCAGACAG.
Amplification was carried out in 30 μL of 1.5 mM
magnesium chloride, 50 pM of each primer, 250 μM
of each deoxyribonucleotide triphosphate (dNTP),
50 ng of template DNA, and 2.5 U of Taq DNA
polymerase (Takara Bio Inc, Otsu, Shiga, Japan). The
polymerase chain reaction (PCR) buffer (10X) was
composed of 100 mM Tris-HCl (pH 8.3), 500 mM
potassium chloride and 15 mM magnesium chloride.
Amplification was performed by initial denaturation at
94°C for 5 minutes, followed by 25 cycles of 30
seconds at 94°C, 1 minute at 56°C, and 3 minutes at
72°C, including a 1-second auto-extension function
resulting in a final extension of 5 minutes at 72°C
using a PTC-200 Peltier thermal cycler (MJ Research,
Watertown, MA, USA). The PCR products (3.6 Kb)
were directly sequenced without further subcloning
on an ABI 377 automated sequencer using the dideoxy-
terminator technology. The sequences of the PCR
products were aligned with the published human
PMP22 cDNA sequences (gi:4505906) to find the
sequence changes.
Results
No PMP22 deletion, duplication or point mutation
were detected in any of the 4 patients. This study
showed negative findings.
Discussion
There were 4 patients in this study who showed clini-
cal symptoms of recurrent polyradiculoneuropathy.
Recurrent GBS was diagnosed in 2 patients and CRP
in the other 2. Unlike the patient reported by Le
Forestier et al,8 the DNA analysis in our cases did not
show PMP22 deletion or point mutation.
Patients with recurrent HNPP have different
pathologic and genetic findings from those who have
recurrent GBS, CRP or CIDP. It is unclear if any
relationship exists between inflammatory poly-
radiculoneuropathies and PMP22 defects.
PMP22 is an integral membrane protein of 160
amino acids with 4 transmembrane domains. PMP22
is expressed by Schwann cells and is localized mainly in
compact peripheral nervous system myelin. It has been
postulated that PMP22 has the function of adhesion
between myelin membranes because it carries the L2/
HNK-1 epitope.12 It has been hypothesized that
PMP22 keeps the myelin lamellae in their mutual
longitudinal position, which prevents them from sliding
along each other. Thus, the loss of 1 gene copy of
PMP22 will disturb the longitudinal adhesion of mye-
lin lamellae.13 Gabriel et al14 used an experimental mo-
del of inflammatory radiculoneuropathy induced by
immunizing rats with PMP22 to show that an immune
response against PMP22 may play a role in the
pathogenesis of the inflammatory neuropathies. One
animal study demonstrated that PMP22 protein could
induce autoantibodies with GBS-like symptoms and
signs in Lewis rats.15 An autoantibody directed at
PMP22 was found in a number of disease states, which
included 70% of patients with Charcot-Marie-Tooth
(CMT) type 1A, 60% of patients with CMT type 2,
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44% of other peripheral neuropathies including CIDP,
anti-MAG (myelin-associated glycoprotein) neuro-
pathy, MFS and diabetic neuropathy, and 23% of
the apparently healthy controls.16 The antibody’s role
in the pathogenesis of these diseases remains to be
determined. Since the pathogenesis of HNPP is
different from that of CRP and GBS, the case with
recurrent polyradiculoneuropathy and the 17P11.2
deletion reported by Le Forestier et al8 might be an
uncommon phenotype of the PMP22 deletion.
The results of the molecular studies in our 4
patients do not support the relationship between
PMP22 deletion and point mutation with recurrent
GBS and CRP. Further large-scale studies are needed
to clarify their relationship.
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